GLP-1 Drug Lawsuits

The Surge in Popularity of Weight Loss Medications

 

When Novo Nordisk first launched Ozempic in 2017, it was intended to treat patients with type 2 diabetes. However, not long after its release, healthcare professionals noticed an unexpected side effect—many individuals prescribed Ozempic began experiencing significant appetite suppression, which led to substantial weight loss in some patients. This unintended use for weight management has since contributed to the surge in GLP-1 Drug Lawsuits, as serious side effects have come to light.

This observation quickly shifted the focus. The popularity of Ozempic’s weight loss effect sparked the development of Wegovy, a higher-dose version of Ozempic specifically designed for weight management. Today, Novo Nordisk manufactures three GLP-1 receptor agonist drugs—Ozempic, Wegovy, and Rybelsus—all containing the active ingredient semaglutide.

 

Understanding Glucagon-like Peptide 1 (GLP-1)

 

GLP-1, short for Glucagon-like Peptide 1, is a hormone naturally produced by the intestines. Its primary role is to help regulate blood sugar levels by:

  • Stimulating insulin release, which helps lower blood sugar
  • Inhibiting the release of glucagon, a hormone that raises blood sugar
  • Slowing gastric emptying, which makes you feel fuller for a longer period and decreases appetite

Because of these effects, GLP-1 receptor agonists like semaglutide have become common treatments not only for type 2 diabetes but also for weight loss management.

 

Examining the Labels: Active Ingredients Behind the Hype

 

These popular weight loss drugs share similarities in their active ingredients, particularly their ability to mimic hormones that regulate appetite and blood sugar.

Semaglutide

Semaglutide is designed to lower blood glucose levels by mimicking the natural GLP-1 hormone your body produces after eating. This hormone also reduces hunger and promotes satiety, which is why semaglutide has been repurposed for weight loss in medications like Wegovy.

 

Tirzepatide

Tirzepatide, the key ingredient in Mounjaro, has gained widespread attention for its significant weight loss potential. It works by activating both GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptors, delivering benefits similar to semaglutide with added impact. Eli Lilly produces two versions of tirzepatide: Mounjaro, approved for type 2 diabetes, and Zepbound, approved for weight loss. Both are administered as once-weekly subcutaneous injections.

 

The Current GLP-1 MDL: What You Should Know

 

As concerns over the safety of these medications grow, individuals who experienced severe side effects have filed lawsuits against the manufacturers of Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound. These cases have been consolidated into a Multidistrict Litigation (MDL).

  • MDL Name: In Re: GLP-1 Receptor Agonists Products Liability Litigation
  • MDL Number: MDL No. 3094
  • Jurisdiction: U.S. District Court for the Eastern District of Pennsylvania
  • Presiding Judge: Honorable Gene E.K. Pratter
  • Defendants: Novo Nordisk (Ozempic, Wegovy, Rybelsus), Eli Lilly (Mounjaro, Zepbound)

The lawsuits allege that these GLP-1 drugs can lead to serious, life-altering complications, including gastroparesis (stomach paralysis), intestinal blockages, and vision loss, and that the manufacturers failed to warn patients and healthcare providers of these risks adequately.

If you or a loved one has suffered adverse effects after using one of these medications, you may be eligible to participate in this litigation.

 

Severe and Potentially Life-Threatening Side Effects

 

While GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro offer benefits in managing type 2 diabetes and promoting weight loss, they have been associated with serious and potentially fatal side effects, including:

 

Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

 

NAION is a rare condition causing sudden vision loss, typically in one eye, due to reduced blood flow to the optic nerve. There is currently no known treatment for this condition. Patients with type 2 diabetes or obesity who take semaglutide may face an increased risk of developing NAION compared to those using non-GLP-1 medications.

 

Intestinal Blockages

 

In 2023, the FDA received multiple reports regarding severe safety concerns tied to these drugs, including cases of life-threatening intestinal blockages. This condition often necessitates major surgical intervention. Symptoms of an intestinal blockage can include:

  • Severe abdominal cramps
  • Bloating
  • Constipation
  • Vomiting
  • Difficulty passing gas

 

Stomach Paralysis (Gastroparesis)

 

Gastroparesis, or stomach paralysis, results when the stomach muscles and nerves fail to function properly, causing food to remain in the stomach longer than normal. Common symptoms include:

  • Persistent indigestion
  • Nausea and vomiting
  • Malnutrition
  • Bloating
  • Feeling full after eating only small amounts
  • Upper abdominal pain
  • Loss of appetite
  • Constipation

 

FDA Updates Ozempic Label With Warning for Intestinal Blockages

 

In 2023, the U.S. Food and Drug Administration (FDA) updated Ozempic’s warning label to include the risk of intestinal blockages or bowel obstructions. This change follows more reports of patients with severe gastrointestinal issues, such as abdominal pain, bloating, constipation, nausea, and vomiting. Intestinal blockages can be life-threatening and may need emergency surgery. This warning highlights safety concerns with GLP-1 receptor agonist medications, like Ozempic, and their potential for serious digestive injuries.

This warning is crucial as Ozempic and similar GLP-1 drugs are widely used for type 2 diabetes and weight loss. Many may not know these new risks, especially those taking the drug off-label for weight management. Understanding the danger of intestinal blockages helps people make informed healthcare decisions, recognize warning signs early, and seek medical attention promptly. It also highlights the need for pharmaceutical manufacturers to be more accountable when severe side effects aren’t adequately disclosed.

 

Why Choose Gallon, Takacs & Boissoneault?

 

At Gallon, Takacs & Boissoneault, we understand the serious health complications that can arise from these medications. Our attorneys are actively reviewing cases for individuals harmed by Ozempic, Wegovy, Mounjaro, Rybelsus, and Zepbound.

With more than 70 years of experience, our firm is committed to holding pharmaceutical companies accountable for the harm they cause. We are here to fight for justice and help you pursue the compensation you deserve.

 

Contact Gallon, Takacs & Boissoneault for a Free Case Evaluation

 

If you or a loved one has suffered from gastroparesis, intestinal blockage, vision loss, or other severe complications after using a GLP-1 receptor agonist drug, we are ready to help. Contact us today for your free consultation. There is no cost to you unless we win your case.